Pancreatic Cancer

News alerts, weekly reports and conference planners

Related cancers:

‹

Pancreatic Ductal Adenocarcinoma (117)

Pancreatic Adenocarcinoma (64)

Pancreatic Ductal Adenocarcinoma (117)

Pancreatic Adenocarcinoma (64)

›

IL1RAP overexpression	Pancreatic Ductal Adenocarcinoma	IL1RAP overexpression	Pancreatic Ductal Adenocarcinoma	CAN04 Sensitive: C3 – Early Trials AACR 2023 - 5 days (New C3) CAN04 Sensitive : C3 AACR 2023 - 5d	CAN04 Sensitive: C3 – Early Trials AACR 2023 - 5 days CAN04 Sensitive : C3 AACR 2023 - 5 days - (New C3)
MTAP deletion	Pancreatic Cancer	MTAP deletion	Pancreatic Cancer	IDE397 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) IDE397 Sensitive : D AACR 2023 - 5d	IDE397 Sensitive: D – Preclinical AACR 2023 - 5 days IDE397 Sensitive : D AACR 2023 - 5 days - (New D)
KRAS Q61H	Pancreatic Ductal Adenocarcinoma	KRAS Q61H	Pancreatic Ductal Adenocarcinoma	RM-046 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) RM-046 Sensitive : D AACR 2023 - 5d	RM-046 Sensitive: D – Preclinical AACR 2023 - 5 days RM-046 Sensitive : D AACR 2023 - 5 days - (New D)
KRAS G12C	Pancreatic Cancer	KRAS G12C	Pancreatic Cancer	ZG19018 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) ZG19018 Sensitive : D AACR 2023 - 5d	ZG19018 Sensitive: D – Preclinical AACR 2023 - 5 days ZG19018 Sensitive : D AACR 2023 - 5 days - (New D)
KRAS mutation	Pancreatic Cancer	KRAS mutation	Pancreatic Cancer	RGT-018 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) RGT-018 Sensitive : D AACR 2023 - 5d	RGT-018 Sensitive: D – Preclinical AACR 2023 - 5 days RGT-018 Sensitive : D AACR 2023 - 5 days - (New D)
KRAS G12D	Pancreatic Ductal Adenocarcinoma	KRAS G12D	Pancreatic Ductal Adenocarcinoma	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) RMC-9805 Sensitive : D AACR 2023 - 5d	RMC-9805 Sensitive: D – Preclinical AACR 2023 - 5 days RMC-9805 Sensitive : D AACR 2023 - 5 days - (New D)
HRD	Pancreatic Ductal Adenocarcinoma	HRD	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) JPI-547 Sensitive : D AACR 2023 - 5d	JPI-547 Sensitive: D – Preclinical AACR 2023 - 5 days JPI-547 Sensitive : D AACR 2023 - 5 days - (New D)
RNF43 mutation	Pancreatic Ductal Adenocarcinoma	RNF43 mutation	Pancreatic Ductal Adenocarcinoma	JPI-547 Sensitive: D – Preclinical AACR 2023 - 5 days (New D) JPI-547 Sensitive : D AACR 2023 - 5d	JPI-547 Sensitive: D – Preclinical AACR 2023 - 5 days JPI-547 Sensitive : D AACR 2023 - 5 days - (New D)
CLDN18.2 expression	Pancreatic Cancer	CLDN18.2 expression	Pancreatic Cancer	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks (New D) SOT102 Sensitive : D ESMO-TAT 2023 - 2wk	SOT102 Sensitive: D – Preclinical ESMO-TAT 2023 - 2 weeks SOT102 Sensitive : D ESMO-TAT 2023 - 2 weeks - (New D)
BRCA2 mutation	Pancreatic Cancer	BRCA2 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : C1	olaparib Sensitive: A1 - Approval olaparib Sensitive : C1
BRCA1 mutation	Pancreatic Cancer	BRCA1 mutation	Pancreatic Cancer	olaparib Sensitive: A1 - Approval olaparib Sensitive : C1	olaparib Sensitive: A1 - Approval olaparib Sensitive : C1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1	gemcitabine + albumin-bound paclitaxel Sensitive: A1 - Approval gemcitabine + albumin-bound paclitaxel Sensitive : A1
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1	5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive: A1 - Approval 5-fluorouracil + leucovorin calcium + nanoliposomal irinotecan Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1	erlotinib Sensitive: A1 - Approval erlotinib Sensitive : A1
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2	GEM-CAP Sensitive: A2 - Guideline GEM-CAP Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	LV5FU2 Sensitive: A2 - Guideline LV5FU2 Sensitive : A2	LV5FU2 Sensitive: A2 - Guideline LV5FU2 Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2	CAPOX Sensitive: A2 - Guideline CAPOX Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Adenocarcinoma	NTRK2 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
NTRK1 fusion	Pancreatic Adenocarcinoma	NTRK1 fusion	Pancreatic Adenocarcinoma	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline 5-fluorouracil + nanoliposomal irinotecan Sensitive : A2	5-fluorouracil + nanoliposomal irinotecan Sensitive: A2 - Guideline 5-fluorouracil + nanoliposomal irinotecan Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2	5-fluorouracil + oxaliplatin Sensitive: A2 - Guideline 5-fluorouracil + oxaliplatin Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2	5-fluorouracil + irinotecan Sensitive: A2 - Guideline 5-fluorouracil + irinotecan Sensitive : A2
NTRK3 fusion	Pancreatic Adenocarcinoma	NTRK3 fusion	Pancreatic Adenocarcinoma	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2	erlotinib Sensitive: A2 - Guideline erlotinib Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2	capecitabine Sensitive: A2 - Guideline capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2	5-fluorouracil + capecitabine Sensitive: A2 - Guideline 5-fluorouracil + capecitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2	gemcitabine Sensitive: A2 - Guideline gemcitabine Sensitive : A2
No biomarker	Pancreatic Adenocarcinoma	No biomarker	Pancreatic Adenocarcinoma	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2	gemcitabine + capecitabine Sensitive: A2 - Guideline gemcitabine + capecitabine Sensitive : A2
BRCA1 mutation	Pancreatic Adenocarcinoma	BRCA1 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
BRCA2 mutation	Pancreatic Adenocarcinoma	BRCA2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
PALB2 mutation	Pancreatic Adenocarcinoma	PALB2 mutation	Pancreatic Adenocarcinoma	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2	cisplatin + gemcitabine Sensitive: A2 - Guideline cisplatin + gemcitabine Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2	FOLFIRINOX Sensitive: A2 - Guideline FOLFIRINOX Sensitive : A2
No biomarker	Pancreatic Cancer	No biomarker	Pancreatic Cancer	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2	gemcitabine + albumin-bound paclitaxel Sensitive: A2 - Guideline gemcitabine + albumin-bound paclitaxel Sensitive : A2
NTRK3 fusion	Pancreatic Cancer	NTRK3 fusion	Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK2 fusion	Pancreatic Cancer	NTRK2 fusion	Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK1 fusion	Pancreatic Cancer	NTRK1 fusion	Pancreatic Cancer	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2	entrectinib Sensitive: A2 - Guideline entrectinib Sensitive : A2
NTRK3 fusion	Pancreatic Cancer	NTRK3 fusion	Pancreatic Cancer	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2	larotrectinib Sensitive: A2 - Guideline larotrectinib Sensitive : A2

Pancreatic Cancer

Associations(407)

Associations
(407)